H2A Clinical Core

肝细胞癌在非洲是一种非常常见和致命的癌症，作为艾滋病毒携带者的患者生活在非洲。 时间长了，肝细胞癌的负担可能会增加。在之前的研究中，我们的团队确认了慢性乙肝感染 C病毒(乙肝病毒、丙型肝炎病毒)、HIV和曼氏血吸虫病是肝细胞癌的独立危险因素。相比较 对美国来说，撒哈拉以南非洲的肝癌发生在较年轻和较晚期的患者中，仅 月份。Makerere大学的同事们提议在东非和西非建立伙伴关系 乌干达、塞内加尔范恩大学和约翰霍普金斯大学专注于艾滋病毒和肝细胞 非洲的癌症(肝癌)：H_2A联盟。建立在长期合作研究、指导的基础上 和临床活动，我们的首要目标是减轻亚洲区的肝癌负担 撒哈拉非洲。我们主张使用适当的医疗手段研究癌症拦截策略。 以阻断或逆转这些引起肝癌的感染的影响。我们将通过以下方式实现这一目标 发展地方能力，开展重要研究。该财团代表着一个综合体 代表东西方的4个国家的研究人员、工作人员、医院和大学之间的伙伴关系 非洲、瑞士和美国，拥有6个临床站点、4个初级实验室和约20名协查人员 英语和法语。临床和数据质量核心(CDQ)旨在支持标准化 严谨地收集、管理和分析财团数据。CDQ将确保高质量的数据 严格收集，临床测量和实验室检测的评估应标准化 在站点之间，有效地进行数据协调，并提供高质量的分析数据集 及时制作。CDQ Core为这两个项目提供支持，并通过 发展核心。对科学和能力发展目标的支持确保 将在联合体项目中全面、系统和严格地收集、管理和分析数据 适当地最大化资源并具有很高的科学影响的可能性。

Hepatocellular carcinoma (HCC) is a very common and lethal cancer in Africa, and as patients with HIV live longer, the HCC burden may increase. In prior studies, our team identified chronic infection with hepatitis B and C viruses (HBV, HCV), HIV and Schistosomiasis mansoni as independent risk factors for HCC. Compared to the US, HCC in sub-Saharan Africa occurs at younger age and more advanced stage with survival of only months. Proposed is an East and West African partnership between colleagues at Makerere University in Uganda, Fann University in Senegal and Johns Hopkins University focused on HIV and hepatocellular carcinoma (HCC) in Africa: The H2A Consortium. Building on long-standing collaborative research, mentoring and clinical activities in both countries, our overarching goal is to reduce the heavy burden of HCC in sub- Saharan Africa. We advocate investigating cancer interception strategies using appropriate medical treatments to interrupt or reverse the impact of these HCC-causing infections. We will accomplish this objective by developing local capacity and performing important research. The Consortium represents a complex partnership between investigators, staff, hospitals, and universities in 4 countries representing East and West Africa, Switzerland and USA, with 6 clinical sites, 4 primary laboratories, and ~20 coinvestigators speaking English and French. The Clinical and Data Quality Core (CDQ) is designed to support the standardized rigorous data collection, management and analysis of Consortium data. CDQ will ensure that high quality data is rigorously collected, that assessment of clinical measurements and laboratory testing be standardized between sites, that data harmonization be effectively performed, and that high quality analytical datasets be produced in a timely manner. CDQ Core provides support for both Projects and to pilot projects through the Developmental Core. Support to both the scientific and capacity development objectives ensures that comprehensive, systematic and rigorous data collection, management and analysis in Consortium projects will appropriately maximize resources and have a high likelihood of scientific impact.